SCHEMBL2421809

SCHEMBL2421809

Cc1ccc(COn2c(-c3ccccc3)nc3ccc([N+](=O)[O-])cc32)cc1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.83
CYP1A2 P05177 4/20 0.83
CYP2C9 P11712 4/20 0.83
POLB P06746 4/20 0.83
TDP1 Q9NUW8 2/20 0.83
CYP2D6 P10635 2/20 0.83
CYP2C19 P33261 2/20 0.83
CTDSP1 Q9GZU7 1/20 0.83
MAPT P10636 8/20 0.81
RAB9A P51151 7/20 0.81
KMT2A Q03164 7/20 0.81
ALDH1A1 P00352 7/20 0.81
NPC1 O15118 5/20 0.81
MEN1 O00255 5/20 0.81
SMN1; SMN2 Q16637 2/20 0.81
CYP3A4 P08684 1/20 0.81
ALOX12 P18054 1/20 0.81
AHR P35869 1/20 0.69
CASP6 P55212 1/20 0.69
L3MBTL1 Q9Y468 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2425706 0.93 RAB9A (0.86) LMNACYP1A2CYP2C9POLBTDP1
SCHEMBL13856816 0.92 LMNA (0.76) LMNACYP1A2CYP2C9POLBTDP1
SCHEMBL14104701 0.89 POLB (0.67) LMNACYP1A2CYP2C9POLBTDP1
SCHEMBL12326646 0.84 RAB9A (0.72) LMNACYP1A2CYP2C9POLBTDP1
SCHEMBL13959573 0.83 RAB9A (0.76) LMNACYP1A2CYP2C9POLBTDP1
SCHEMBL14104700 0.82 RAB9A (0.69) LMNACYP1A2CYP2C9POLBTDP1
SCHEMBL2420953 0.82 RAB9A (0.68) LMNACYP1A2CYP2C9POLBTDP1
SCHEMBL13844372 0.82 RAB9A (0.69) LMNACYP1A2CYP2C9POLBTDP1
SCHEMBL12326650 0.81 RAB9A (0.76) LMNACYP1A2CYP2C9POLBTDP1
SCHEMBL12325958 0.81 RAB9A (0.72) LMNACYP1A2CYP2C9POLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170189477-A1 Methods and Compositions of P27KIP1 Transcriptional Modulators NIH-DEITR 2017-07-06 US claimed
US-9572815-B2 Methods and compositions of p27KIP1 transcriptional modulators ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2017-02-21 US claimed
US-20160030445-A1 METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTIONAL MODULATORS ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2016-02-04 US claimed
WO-2014145205-A2 METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTION MODULATORS ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2014-09-18 WO claimed
US-8188131-B2 Compounds that enhance Atoh1 expression MASSACHUSETTS EYE & EAR INFIRMARY (US) 2012-05-29 US claimed
EP-2254572-A2 COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION Massachusetts Eye & Ear Infirmary (US) 2010-12-01 EP claimed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US claimed
WO-2009100438-A2 COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-08-13 WO claimed
US-20250099539-A1 METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS MASSACHUSETTS EYE AND EAR INFIRMARY 2025-03-27 US disclosed
US-12239651-B2 Treatment of hearing loss MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2025-03-04 US disclosed
US-12156899-B2 Methods and compositions for regenerating hair cells and/or supporting cells MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2024-12-03 US disclosed
US-20240299432-A1 TREATMENT OF HEARING LOSS MASSACHUSETTS EYE AND EAR INFIRMARY 2024-09-12 US disclosed
US-12043653-B2 Efficient delivery of therapeutic molecules to cells of the inner ear MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2024-07-23 US disclosed
US-11963968-B2 Treatment of hearing loss MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2024-04-23 US disclosed
EP-1558341-A2 TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF Paratek Pharmaceuticals, Inc. (US) 2005-08-03 EP disclosed
US-20050124678-A1 Transcription factor modulating compounds and methods of use thereof PARATEK PHARMACEUTICALS, INC. (US) 2005-06-09 US disclosed
EP-1524974-A2 TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF Paratek Pharmaceuticals, Inc. (US) 2005-04-27 EP disclosed
WO-2004041209-A2 TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF PARATEK PHARMACEUTICALS, INC. (US) 2004-05-21 WO disclosed
WO-2004001058-A2 TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF PARATEK PHARMACEUTICALS, INC. (US) 2003-12-31 WO disclosed
US-20030229065-A1 Transcription factor modulating compounds and methods of use thereof PARATEK PHARMACEUTICALS, INC. 2003-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299432-A1 TREATMENT OF HEARING LOSS HES1, NOTCH1, NOTCH4 LMNA 2942/4885CYP1A2 4835/4885CYP2C9 4861/4885
US-12043653-B2 Efficient delivery of therapeutic molecules to cells of the inner ear HES1, NOTCH1, NOTCH2 LMNA 2342/4885CYP1A2 4807/4885CYP2C9 4875/4885
US-20170189477-A1 Methods and Compositions of P27KIP1 Transcriptional Modulators WNT1, CTNNB1, CTNNBL1 LMNA 1730/4885CYP1A2 4047/4885CYP2C9 4461/4885
US-20030229065-A1 Transcription factor modulating compounds and methods of use thereof RELA, ATF4, JUN LMNA 4220/4885CYP1A2 4268/4885CYP2C9 4741/4885
US-12156899-B2 Methods and compositions for regenerating hair cells and/or supporting cells HES1, NOTCH1, NOTCH4 LMNA 488/4885CYP1A2 4810/4885CYP2C9 4860/4885
US-20050124678-A1 Transcription factor modulating compounds and methods of use thereof JUN, CREBBP, TFEB LMNA 3323/4885CYP1A2 3557/4885CYP2C9 3774/4885
US-20250099539-A1 METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS HES1, NOTCH1, NOTCH4 LMNA 488/4885CYP1A2 4810/4885CYP2C9 4860/4885
US-20160030445-A1 METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTIONAL MODULATORS WNT1, CTNNB1, CTNNBL1 LMNA 1564/4885CYP1A2 4175/4885CYP2C9 4513/4885
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION DACH1, EZH1, CREBBP LMNA 3060/4885CYP1A2 3913/4885CYP2C9 4807/4885
US-12239651-B2 Treatment of hearing loss HES1, NOTCH1, NOTCH4 LMNA 2942/4885CYP1A2 4835/4885CYP2C9 4861/4885
US-11963968-B2 Treatment of hearing loss HES1, NOTCH1, NOTCH4 LMNA 2942/4885CYP1A2 4835/4885CYP2C9 4861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.